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remained unchanged. In conclusion, ramipril reduced 
indices of aortic stiffness, suggesting that angiotensin 
converting enzyme inhibitor therapy may have effects 
beyond blood pressure reduction. However, treatment did 
not appear to influence endothelial function. Evidence of 
endothelial dysfunction and its possible improvement by 
antihypertensive treatment might require more advanced 
hypertension.
This study is registered at ClinicalTrials.gov 
(NCT02901977) and at EudraCT (# 2007-000631-25).
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Introduction
Hypertension is characterized by an increased sympa-
thetic vascular tone, early vascular remodelling of small 
resistance arteries, and impaired endothelial function 
[1–3]. Thus, hypertension increases pulsatile load on the 
vasculature, which induces aortic stiffness and increases 
pulse wave velocity (PWV). This further changes pulse 
wave reflection, resulting in augmentation of the reflec-
tive retrograde pulse wave and an increase in central aortic 
blood pressure (BP). Compared to the peripheral BP, val-
ues on central BP, augmentation index (AIx), aortic stiff-
ness, and arterial stiffness of different vascular regions give 
additional information about future cardiovascular events 
[4–6]. Furthermore, aortic dilatation, increased aortic stiff-
ness, AIx, and central pulse pressure are associated with 
endothelial dysfunction of conduit arteries [7–10], and 
Abstract We aimed to study whether inhibition of the 
renin–angiotensin–aldosterone system has effects on vas-
cular structure and function beyond the effects on blood 
pressure reduction alone. Patients with mild-to-moderate 
hypertension (n = 61, age 54 ± 12 years, 34% women) 
received the angiotensin converting enzyme inhibitor rami-
pril 10 mg or the alpha 1-adrenoceptor blocker doxazosin 
8 mg double-blind for 12 weeks. Aortic blood pressure, 
pulse wave velocity, and augmentation index were assessed 
by applanation tonometry. Endothelial function was stud-
ied by forearm post-ischemic flow mediated vasodilatation 
and by pulse wave analysis with beta 2-adrenoceptor ago-
nist stimulation. Skin microvascular reactivity was assessed 
by laser Doppler fluxmetry and iontophoresis. Treatment 
with doxazosin or ramipril reduced aortic and brachial 
blood pressures (all P < 0.001), with greater reductions in 
aortic than brachial systolic blood pressures (P = 0.021) 
and aortic/brachial pulse pressure ratio (P = 0.005). Com-
pared to doxazosin, ramipril reduced carotid-femoral and 
carotid-radial pulse wave velocity (both P < 0.05). Fore-
arm endothelial dependent and independent vasodilatation, 
assessed by post-ischemic flow mediated vasodilatation and 
glyceryl trinitrate, and by pulse wave analysis remained 
unchanged by both doxazosin and ramipril. In addition, 
skin microvascular endothelial dependent (acetylcholine) 
and independent vasodilatation (sodium nitroprusside) 
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endothelial dysfunction is associated with an increased risk 
of cardiac events [11].
Antihypertensive treatment plays a key role to reverse 
hypertension induced structural vascular changes. Activa-
tion of the renin–angiotensin–aldosterone system (RAAS) 
increases the formation of angiotensin II, which mediates 
vasoconstriction and promotes inflammation, endothelial 
dysfunction, oxidative stress, and structural vascular changes 
[12]. Angiotensin converting enzyme (ACE) inhibitors and 
angiotensin receptor blockers may have effects beyond BP 
lowering to reverse vascular remodelling [13–16]. How-
ever, the reported effects of blocking the RAAS on endothe-
lial function are conflicting and the mechanisms remain to 
be clarified [17–19]; and systematic comparisons to block-
ing sympathetic vasoconstrictor nerve activity by alpha 
1-adrenoceptor blockers are not present [20, 21]. Further-
more, ACE inhibitors appear to reduce arterial stiffness 
independent of their ability to reduce BP, but it remains 
unclear whether they are superior to other antihypertensive 
drug classes; and the effects of alpha 1-adrenoceptor block-
ers have not been well studied [22, 23]. ACE inhibitors have 
been proposed to improve cardiovascular outcome in high-
risk patients beyond the effects of BP reduction [24, 25]. 
However, the possible additional effects of various antihy-
pertensive drug classes on clinical outcome beyond their 
reduction in BP remain to be clarified [26].
This study aimed to investigate the possible influence 
of the RAAS on indices of central and peripheral vascular 
structure and function, and on endothelial function beyond 
the effects on blood pressure. Thus, we compared the 
effects of blocking the RAAS by the ACE inhibitor rami-
pril to reducing noradrenergic sympathetic vascular tone 
by the alpha 1-adrenoceptor blocker doxazosin in patients 
with uncomplicated mild-to-moderate hypertension. We 
assessed central BP and indices of aortic stiffness by pulse 
wave analysis, and endothelial function was examined by 
several methods in the forearm skeletal muscle and in the 
skin microcirculation, to reflect both conduit and resistance 
artery function.
Materials and methods
Study design and subjects
Women and men 18 years of age or older with mild-to-
moderate primary hypertension were considered eligi-
ble for the Doxazosin–Ramipril Study if their office BP, 
obtained as a mean of 2 or more measurements by stand-
ard techniques in the supine position with an appropriate 
cuff size and mercury sphygmomanometer, was >140 mm 
Hg systolic and/or >90 mm Hg diastolic. Ambulatory BP 
monitoring had been performed in most patients to confirm 
the diagnosis of hypertension. All subjects were previously 
untreated or free from antihypertensive or other drug ther-
apy with potential influence on BP, vascular, or endothelial 
function for at least 4 weeks. Secondary hypertension was 
ruled out by physical examination and routine biochemical 
examinations. Patients with BP >180/110 mm Hg, coronary 
artery disease, congestive heart failure, or atrial fibrillation 
or flutter, diabetes mellitus, or chronic kidney disease were 
excluded.
Randomization to double-blind treatment with doxazo-
sin 4 mg od or ramipril 5 mg od for 2 weeks with forced 
titration to doxazosin 8 mg od and ramipril 10 mg od for 
an additional 10 weeks was performed by a computer-gen-
erated list in blocks of four, stratified by sex. The two study 
drugs had identical appearance and were provided in iden-
tical containers for each patient, with the contents blinded 
for both patient and investigator (Apoteket Produktion & 
Laboratorier AB, Stockholm, Sweden).
The study included 71 patients (63 with never treated 
hypertension); 10 patients (5 women and 5 men) discontin-
ued due to reported side-effects (8 on doxazosin and 2 on 
ramipril). No serious side-effects were reported. Thus, we 
here report on 61 patients (56 were never treated for hyper-
tension, and 3 previously treated with amlodipine, 1 with 
metoprolol, and 1 with enalapril). All participants achieved 
the targeted 10 weeks of treatment with 8 mg doxazosin od 
or 10 mg ramipril od. Only 2 women on ramipril and 1 on 
doxazosin were premenopausal (i.e. <45 years of age), and 
no participant used systemic used hormone replacement 
therapy.
Patients arrived in the morning after fasting overnight 
for the investigations at weeks 0 and 12. They were under-
taken on 2 consecutive days on both occasions, to avoid 
pharmacological interference of the examination protocols 
on vascular function. The patients were asked to take their 
study medication approximately 2 h before the investiga-
tions to achieve peak plasma concentrations, but to refrain 
from caffeine containing beverages, fruit juices or vitamin 
C, and any other medication (including thrombocyte inhibi-
tory drugs for 7 days and non-steroid anti-inflammatory 
drugs for 48 h). Examinations were performed in the supine 
position following a 20 min period of rest in a quiet room 
kept at 21–24 °C constant temperature.
Blood pressure measurements and pulse wave analysis
For the purpose of the vascular function studies, brachial 
BP was obtained in the supine position by an oscillomet-
ric device (OMRON 705IT, OMRON Healthcare Co., Ltd. 
Kyoto Japan) on the right arm with an appropriately sized 
cuff as a mean of three readings 1 min apart.
Applanation tonometry was performed using a Sphyg-
moCor device (AtCor Pty Ltd, West Ryde, NSW, Australia) 
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according to current recommendations [27]. Radial artery 
waveforms were calibrated using brachial systolic and dias-
tolic BP measured in the same arm (vide supra), the central 
aortic waveform was calculated by device software using 
the generalized transfer function, and central BP values 
were derived. AIx was measured through the software. 
Recordings were then repeated at the level of the common 
carotid artery and the femoral artery, and PWV was calcu-
lated from the direct (carotid-to-radial and carotid-to-femo-
ral) path length.
Pulse pressure was calculated as systolic minus dias-
tolic BP. Mean arterial pressure was calculated as diastolic 
BP + 1/3 x pulse pressure. Body mass index (in kg/m2) was 
calculated as weight/height2.
Assessment of endothelial function
Endothelium dependent flow mediated vasodilatation 
(FMD) was measured by ischemia induced reactive hyper-
aemia in the non-dominant arm according to current rec-
ommendations [28]. Vasodilatation was induced by infla-
tion of a pneumatic tourniquet placed around the forearm 
to a pressure of 250 mm Hg for 5 min, followed by release. 
Brachial artery diameter was measured proximal to the 
tourniquet by a Vivid 7 Dimension (GE Medical System, 
Horten, Norway) ultrasound device and a 9 MHz linear 
transducer. All images were stored for later analyses. The 
mean values of 3 measurements of arterial diameter per-
formed at end diastole were calculated at rest and at 30, 60, 
and 90 s after cuff release. The maximal relative increase in 
diameter was taken as a measure of FMD. After a period of 
at least 10 min to regain stable resting conditions, 0.4 mg 
glyceryl trinitrate (Nitrolingual, G Pohl-Boskamp GmbH 
& Co KG, Hohenlockstedt, Germany) given as sublingual 
spray was used to assess endothelium-independent vasodil-
atation. Relative changes in artery diameter were calcu-
lated from rest to 4 min following drug administration. To 
better assess endothelial function, we also calculated the 
endothelial function index by the ratio of the maximum 
relative increase in flow by reactive hyperaemia to glyc-
eryl trinitrate, as previously proposed [29]. We calculated 
local shear stress, an important stimulus for FMD, as 8 x 
µ x blood flow velocity/baseline brachial artery diameter, 
where µ is blood viscosity, which was assumed to be 0.035 
dyne x s/cm2 [30]. The inter-assay coefficient of variation 
for FMD in our laboratory is 15% (n = 20).
Endothelial function was also assessed by beta 2-adreno-
ceptor agonist induced changes in the pulse waveform [31]. 
Radial artery pulse waves were recorded by applanation 
tonometry, and the maximal systolic peak and the reflected 
waves were identified by the calculations of the first and 
second derivatives of the pulse curve. The relative height 
of the diastolic reflected wave (i.e., the reflection index) 
was used as an index of endothelial function [32] After a 
recording under resting conditions, 0.25 mg terbutaline 
(Bricanyl, AstraZeneca, Mölndal, Sweden) was given sub-
cutaneously in the upper forearm and the pulse waveform 
was again evaluated after 15 and 20 min. The maximal rel-
ative change was used. A large reduction of the reflection 
index indicates a good response.
Endothelium dependent and independent forearm skin 
microvascular vasodilatation was assessed by laser Doppler 
fluxmetry and transcutaneous iontophoretic administration 
(Periflux system 5000, PF 5010 LDPM Unit, PF5010 Temp 
Unit, and 481-1 Single Probe, Perimed, Järfälla, Sweden) 
of small amounts of acetylcholine (Sigma-Aldrich AB, 
Stockholm, Sweden) and sodium nitroprusside (Hospira, 
Inc., Lake Forest, IL, USA) for 60 s, as described previ-
ously [33]. Skin microvascular peak flux was recorded con-
tinuously up to 16 min after iontophoresis, and is expressed 
in arbitrary units. We also determined maximum skin 
microvascular hyperaemia by peak flux induced by local 
heating of forearm skin to 44 °C for 6 min.
Biochemistry
Routine biochemistry was analysed by standard proce-
dures from fasting blood samples obtained into Vacutainer 
tubes (Becton–Dickinson Co. Cedex, Meylan, France) on 
ice from an indwelling antecubital venous catheter after 
20 min of supine rest.
Statistics
The co-primary outcomes in the Doxazosin–Ramipril 
Study were changes in endothelial function assessed by 
FMD and in haemostatic function measured by the genera-
tion of thrombin–antithrombin complex (those results will 
be presented elsewhere). A meta-analysis indicates a 1% 
increase in FMD to be associated with a 13% lower risk 
for a future cardiovascular event, after adjustment for con-
founding risk factors [34]. Thus, assuming 2 alpha 0.05 
and beta 0.80, we calculated a study population of 2 × 24 
subjects sufficient to detect a 0.6% difference in FMD by 
treatment between the two study groups (with an SD of 
0.72% in our laboratory) sufficient to ascertain a clini-
cally important difference; and 2 × 26 subjects sufficient to 
detect a clinically relevant 0.4 mg/l difference in thrombin–
antithrombin complex by treatment between the two groups 
(with an SD of 0.5 mg/l in our laboratory). Assuming 
that patients may be lost due to withdrawals, side-effects, 
technical, or analytical problems, we intended to include 
70 subjects to have at least 60 completed patients and to 
ensure a sufficient number of evaluable patients.
Data are presented as mean values ± SD (or mean val-
ues ± SEM for calculated differences) or medians and 
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interquartile range, as appropriate. Skewed variables were 
logarithmically transformed. Group comparisons were 
made by the analysis of variance or by multivariate anal-
ysis of variance. Multiple linear regression analysis was 
used to assess effects of treatment. To account for potential 
confounders concerning PWV and AIx, the initial multi-
variate mode always included baseline mean arterial pres-
sure, heart rate, height, and age; gender did not affect the 
results. All results were similar if mean arterial pressures 
at week 12 instead of baseline values were included in the 
model. All statistical tests were 2-sided and carried out to 
a significance level (P) of 0.05. The statistical program 




Background characteristics of the two study groups are 
presented in Table 1. The two study groups were compa-
rable and there were no significant differences between 
the groups. Outpatient office BP values at inclusion were 
150 ± 8/92 ± 10 and 155 ± 9/94 ± 7 mm Hg in patients 
eventually randomized to doxazosin and ramipril, respec-
tively. Aortic and brachial BP and heart rate values 
(recorded in the laboratory at the time of the investigation), 
and indices of central vascular function were also similar 
in the two groups (Table 2). Aortic and brachial pulse pres-
sures were 49.5 ± 9.6 and 59.0 ± 8.1 mm Hg (P < 0.001) in 
the doxazosin group, and 51.4 ± 13.6 and 60.3 ± 9.7 mm 
Hg (P < 0.001) in the ramipril group, respectively. 
Effects on central and peripheral BP by treatment
Antihypertensive drug treatment reduced aortic and bra-
chial BP in both study groups (Table 2; Fig. 1). Of note, 
the changes in aortic and brachial systolic BP were greater 
by ramipril than by doxazosin (Table 2; Fig. 1). Drug treat-
ment reduced aortic systolic BP more than brachial BP 
(P = 0.021) with no difference between doxazosin and 
ramipril.
Drug treatment reduced aortic pulse pressure more than 
brachial pulse pressure (Fig. 1). The changes in aortic 
and brachial pulse pressure were −2.6 ± 5.7 (P = 0.030) 
and −1.4 ± 6.0 (P = 0.22) mm Hg for doxazosin, and 
−7.5 ± 8.7 (P < 0.001) and −4.2 ± 8.2 (P = 0.006) 
mm Hg for ramipril, respectively. Although the absolute 
changes in aortic (but not brachial) pulse pressure were 
greater (P = 0.016) in the ramipril group, the changes in 
the aortic to brachial pulse pressure ratios were similar in 
the two groups (Table 2).
Effects on vascular function by treatment
Compared to doxazosin, ramipril reduced carotid-femoral 
PWV and carotid-radial PWV (also when mean arterial 
pressure, heart rate, height, age, and gender were consid-
ered) (Table 2; Fig. 1). There was no difference between 
the doxazosin and ramipril groups in the ratio carotid-
femoral to carotid-radial PWV (Table 2; Fig. 1). AIx was 
Table 1  Baseline 
characteristics
Data presented as mean values ± SD, if not otherwise stated
Doxazosin Ramipril All
n 28 33 61
Male/female (n) 20/8 20/13 40/21
Age, years (range) 53.5 ± 11.3 (26-75) 53.7 ± 13.3
(23-70)
53.6 ± 12.3 (23-75)
Smoker (n) 2 2 4
Height (cm) 176.4 ± 7.6 173.5 ± 9.3 174.9 ± 8.6
Body mass index (kg/m2) 27.8 ± 5.4 25.8 ± 3.8 26.7 ± 4.7
Office systolic blood pressure (mm Hg) 150.5 ± 7.9 154.8 ± 9.3 152.5 ± 8.9
Office diastolic blood pressure (mm Hg) 92.2 ± 9.8 93.57 ± 7.1 92.9 ± 8.4
Baseline systolic blood pressure (mm Hg) 148.0 ± 10.9 148.3 ± 11.3 148.2 ± 11.1
Baseline diastolic blood pressure (mm Hg) 89.0 ± 10.3 88.0 ± 8.1 88.5 ± 9.1
Heart rate (min−1) 59 ± 9 62 ± 8 61 ± 8
Total cholesterol (mmol/L) 5.4 ± 1.2 5.4 ± 0.9 5.4 ± 1.1
Fasting plasma glucose (mmol/L) 5.5 ± 0.6 5.3 ± 0.5 5.4 ± 0.6
Creatinine (µmol/L) 78.6 ± 13.5 74.5 ± 14.6 76.5 ± 14.1
Haematocrit (%) 41.1 ± 3.2 41.3 ± 2.4 41.2 ± 2.8
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numerically reduced in both study groups, although this did 
not reach significance (Table 2; Fig. 1).
Effect on endothelial function by treatment
Data on brachial artery diameter and function are presented 
in Table 3. Indices of gross endothelial dependent and 
independent vasodilatation, assessed by forearm vascular 
function in response to post-ischemic FMD and glyceryl 
trinitrate, and by the reflection index derived from pulse 
wave analysis and beta 2-adrenoceptor agonist stimulation, 
remained unchanged by treatment with doxazosin or rami-
pril (Table 4). In addition, endothelial dependent and inde-
pendent vasodilatation assessed in the skin microcircula-
tion remained unchanged by treatment (Table 5).
Discussion
This study in patients with uncomplicated mild-to-
moderate hypertension compared the effects of reduc-
ing noradrenergic sympathetic vascular tone by the alpha 
Table 2  Treatment effects on 
blood pressure and vascular 
function
Mean values ± SD at week 0 and 12 for 27–33 subjects in each treatment group, including all subjects 
with valid measurements at week 0 or 12. Relative differences (∆%) for paired observations are presented 
in Fig. 1. P denotes significant changes by repeated-measures MANOVA, where PWV car-fem, PWV car-
rad, and augmentation index were adjusted for mean arterial pressure, heart rate, height, and age; gender 
did not affect the results
SBP br brachial systolic blood pressure, SBP ao aortic systolic blood pressure, DBP br brachial diastolic 
blood pressure, DBP ao aortic diastolic blood pressure, PWV car-fem carotid-femoral pulse wave velocity, 
PWV car-rad carotid-radial pulse wave velocity, PP ao/PP br aortic pulse pressure/brachial pulse pressure
Week Doxazosin Ramipril P by repeated-measures 
ANOVA
SBP br (mm Hg) 0 148.0 ± 11.0 148.3 ± 16.3 Time <0.001
12 142.3 ± 12.1 136.2 ± 11.6 Group 0.27
Time × group 0.030
SBP ao (mm Hg) 0 140.3 ± 12.9 139.2 ± 15.8 Time <0.001
12 131.7 ± 14.8 124.7 ± 13.3 Group 0.19
Time × group 0.039
DBP br (mm Hg) 0 89.0 ± 10.3 88.0 ± 8.1 Time <0.001
12 84.6 ± 10.3 80.1 ± 8.7 Group 0.21
Time × group 0.073
DBP ao (mm Hg) 0 90.9 ± 10.0 87.8 ± 7.5 Time <0.001
12 85.2 ± 10.5 80.8 ± 7.1 Group 0.058
Time × group 0.35
Heart rate (min-1) 0 58.9 ± 7.6 61.9 ± 8.1 Time 0.79
12 58.8 ± 9.7 61.3 ± 7.4 Group 0.14
Time × group 0.90
PWV car-fem (m/s) 0 8.5 ± 1.5 8.9 ± 2.0 Time 0.070
12 8.3 ± 1.7 8.4 ± 1.9 Group 0.42
Time × group 0.037
PWV car-rad (m/s) 0 8.7 ± 1.5 9.1 ± 1.0 Time 0.38
12 8.7 ± 1.2 8.4 ± 1.1 Group 0.43
Time × group 0.034
Augmentation index (%) 0 29.3 ± 10.4 30.7 ± 13.6 Time 0.37
12 27.1 ± 11.4 26.8 ± 12.1 Group 0.78
Time × group 0.37
PP ao/PP br 0 0.83 ± 0.12 0.85 ± 0.14 Time 0.005
12 0.81 ± 0.14 0.78 ± 0.12 Group 0.72
Time × group 0.21
PWV car-fem/PWV car-rad 0 0.98 ± 0.18 0.97 ± 0.19 Time 0.55
12 0.94 ± 0.18 1.02 ± 0.22 Group 0.38
Time × group 0.39
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1-adrenoceptor blocker doxazosin to blocking the RAAS 
by the ACE inhibitor ramipril to assess the possible influ-
ence of the RAAS on vascular structure and function 
beyond the effects on blood pressure. As expected, treat-
ment with both doxazosin and ramipril for 12 weeks 
reduced brachial systolic and diastolic BP. This confirms 
an important role for both sympathetic vasoconstrictor 
nerve activity mediated by noradrenaline and for the RAAS 
through actions of angiotensin II in the control of vascu-
lar smooth muscle tone and BP in man. Furthermore, we 
found greater treatment induced reductions in aortic than 
in brachial systolic BP, and this did not differ between the 
two drugs. Our observations of larger reductions in central 
than in peripheral BP on ramipril are in agreement with 
findings with other ACE inhibitors [35, 36]. More impor-
tant, our findings with doxazosin appear novel, as the 
effects of alpha-adrenoceptor blockers on central BP have 
not been well studied. Of note, beta-adrenoceptor block-
ers appear to have less effect on central BP, as compared to 
other drug classes [36]. Thus, both neurogenic sympathetic 
Fig. 1  Relative changes (mean 
values ± SEM) in BP and 
vascular function by treatment. 
Significant treatment induced 
changes between groups are 
shown as *P < 0.05. Further sta-




vasoconstriction and the RAAS are important for the con-
trol of central and peripheral BP.
Carotid-femoral PWV provides a good reflection of aor-
tic stiffness, and antihypertensive treatment reduces PWV. 
Compared to doxazosin, ramipril reduced carotid-femoral 
PWV. These results persisted when accounted for poten-
tial confounding influence (i.e., mean arterial pressure, 
heart rate, height, age, and gender). This is in agreement 
with the previous observations that inhibition of the RAAS 
with ACE inhibitors or angiotensin receptor blockers [37–
39] reduces (i.e., improves) aortic stiffness. However, the 
effects of doxazosin on indices of aortic stiffness in this 
study were minor. These results are novel, as the effects 
of alpha 1-adrenoceptor blockers on aortic stiffness have 
been little studied. One uncontrolled study in 11–15 Asian 
hypertensive patients suggested a low dose of doxazosin for 
12 months to improve proximal aortic stiffness [40], and 
results reported in preliminary form suggested a reduction 
in PWV by doxazosin similar to that of a thiazide diuretic 
[41]. These results are in contrast to ours but may, at least 
in part, be due to differences in study design, population, 
and methodology. Thus, antihypertensive drug therapy by 
ramipril reduces aortic stiffness within 12 weeks of treat-
ment, suggesting that the effects of ACE inhibitor therapy 
go beyond the effects of BP reduction, as also proposed by 
others [22].
Pulse pressure amplification, as compared to brachial 
pulse pressure, reflects pulsatile flow and gives informa-
tion about central haemodynamic and microvascular dam-
age. Thus, central pulse pressure is an indirect indicator 
of central aortic stiffness [42]. Accordingly, our findings 
with ramipril on carotid-femoral PWV were accompa-
nied by consistent changes in other measures of pulsatile 
load, including reduced central pulse pressure, Aix (which 
mainly reflects peripheral resistance), and carotid-radial 
PWV (which reflects stiffness of peripheral conduit arter-
ies), also when potential confounding influence (i.e. mean 
arterial pressure, heart rate, height, age, and gender) was 
considered. Thus, whereas alpha 1-adrenoceptor blockade 
seems to have little effect on arterial stiffness, ACE inhibi-
tors may have additional beneficial effects beyond those 
related to BP reduction. This may be mediated by block-
ing the vasoconstrictor effects of angiotensin II, effects on 
structural vascular remodelling with hypertrophy and fibro-
sis, or by improved endothelial function [43, 44]. However, 
given the small effects by treatment on endothelial function 
(see below), alterations in endothelial function were less 
likely important for our results.
In this study, doxazosin or ramipril did not change 
post-ischemic FMD (considered to reflect mainly con-
duit artery endothelium dependent vasodilatation) or 
the forearm blood flow response to glyceryl trinitrate. 
These results were consistent also when the ratio FMD 
to glyceryl trinitrate (i.e., endothelial function index) 
was calculated, suggesting that drug treatment did not 
alter endothelial function. Consistent with these findings, 
endothelial dependent vasodilatation assessed by pulse 
wave analysis before and after beta 2-agonist stimulation 
(considered to reflect mainly resistance artery endothe-
lium dependent vasodilatation) revealed little effect on 
reflection index by treatment with doxazosin or ramipril. 
In hypertensive patients with established coronary artery 
disease, suggesting more advanced atherosclerotic vascu-
lar disease, the ACE inhibitor quinapril, but not enalapril 
Table 3  Forearm circulatory variables before and during post-
ischemic hyperaemia
Mean values ± SD; 23–32 subjects in each treatment group, includ-
ing all subjects with valid measurements at week 0 or 12. P denotes 
significant changes by repeated-measures MANOVA
Doxazosin Ramipril P by repeated-meas-
ures ANOVA
Baseline brachial artery diameter (mm)
 Week 0 3.87 ± 0.51 3.70 ± 0.69 Time 0.36
 Week 12 3.88 ± 0.52 3.78 ± 0.64 Group 0.34
Time × group 0.52
Baseline mean flow velocity (cm/s)
 Week 0 5.2 ± 3.1 4.4 ± 3.1 Time 0.31
 Week 12 5.5 ± 2.7 4.9 ± 2.8 Group 0.29
Time × group 0.73
Hyperaemic mean flow velocity (cm/s)
 Week 0 37.2 ± 9.8 38.2 ± 8.7 Time 0.96
 Week 12 41.3 ± 20.7 32.8 ± 7.5 Group 0.14
Time × group 0.07
Baseline mean flow (ml/min)
 Week 0 61.8 ± 39.2 52.2 ± 41.2 Time 0.40
 Week 12 65.2 ± 35.3 56.4 ± 38.6 Group 0.31
Time × group 0.92
Hyperaemic mean flow (ml/min)
 Week 0 491.9 ± 171.2 454.3 ± 179.1 Time 0.95
 Week 12 526.3 ± 36.8 395.1 ± 134.6 Group 0.0271
Time × group 0.035
Hyperaemic/baseline mean flow ratio
 Week 0 10.5 ± 6.1 14.2 ± 11.7 Time 0.70
 Week 12 12.7 ± 14.6 10.8 ± 9.8 Group 0.73
Time × group 0.20
Baseline local shear stress (dyne/cm2)
 Week 0 3.9 ± 2.3 3.2 ± 2.1 Time 0.28
 Week 12 4.1 ± 2.3 3.8 ± 2.0 Group 0.33
Time × group 0.68
Hyperaemic local shear stress (dyne/cm2)
 Week 0 28.2 ± 8.0 29.1 ± 8.3 Time 0.92
 Week 12 27.6 ± 8.3 26.5 ± 7.8 Group 0.64
Time × group 0.08
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or the angiotensin receptor blocker losartan, improved 
endothelial function [45], whereas ramipril seemed to 
improve FMD in hypertensive patients in a dose-depend-
ent manner [46]. Similarly, the effects on endothelial 
function by angiotensin receptor blockers in hyperten-
sion are not uniform [18, 19]. There is little reported on 
the effects of alpha 1-adrenoceptor blockers on endothe-
lial function. A low dose of doxazosin for 12 months 
improved endothelial function in one small, uncontrolled 
study [40], whereas another small placebo controlled 
cross-over study demonstrated improved endothelial func-
tion by doxazosin [47].
We also investigated skin microcirculation by laser Dop-
pler fluxmetry during iontophoresis of acetylcholine and 
sodium nitroprusside, and by local heating of the skin to 
evaluate treatment induced effects on endothelial func-
tion. This technique in the skin circulation has been shown 
sensitive to detect the early disturbances in endothelial 
function in man [33]. However, our results do not suggest 
alterations in skin microcirculation endothelial function 
by treatment with doxazosin or ramipril. Alpha 2-adreno-
ceptors are present on vascular smooth muscle endothelial 
cells and on the endothelium, where they mediate oppos-
ing effects on vascular tone. There is evidence that alpha 
2-adrenoceptor agonist stimulation interfere with cutaneous 
microcirculation vasodilatation capacity after post-occlu-
sive reactive hyperaemia, with increased production of 
nitric oxide [48]. However, little is published on the effects 
of alpha 1-adrenoceptor blockers and skin microcirculation 
in man [48, 49]. Concerning the RAAS, cross-sectional 
data suggest that skin microcirculation endothelial function 
was better in hypertensive patients treated with a combi-
nation of an ACE inhibitor and a diuretic (perindopril and 
indapamide), as compared to patients receiving treatment 
excluding an ACE inhibitor and/or a diuretic [50]. In con-
trast, endothelial function was improved similarly after 
6 months treatment by the beta-adrenoceptor blocker meto-
prolol and the angiotensin receptor blocker olmesartan in 
another study [51].
Taken together, our results with three different validated 
non-invasive techniques to investigate endothelial function 
in various peripheral vascular beds were consistent. They 
suggest that antihypertensive treatment by reducing noradr-
energic sympathetic vascular tone or by blocking the RAAS 
for 12 weeks does not influence endothelial dependent or 
independent vasodilation. However, these results should be 
interpreted with caution as the study population was rela-
tively small and the variability of the methods for assessing 
endothelial function is not trivial. Nevertheless, this may be 
taken to suggest that our study population with uncompli-
cated mild-to-moderate hypertension had relatively normal 
endothelial function, where treatment induced improve-
ment is difficult to detect. This is in consort with the obser-
vation that vascular remodelling develops at an earlier stage 
than endothelial dysfunction in hypertension [3]. More 
advanced hypertensive disease conditions with vascular 
dysfunction evident by coronary artery disease, diabetes, or 
other concomitant disease may be required to demonstrate 
Table 4  Assessment of 
endothelial function by 
treatment
Mean values ± SD for relative changes before and following drug treatment for 23–32 subjects in each 
treatment group, including all subjects with valid measurements at week 0 or 12, and absolute changes 
by treatment (∆, mean values ± SEM). P denotes significant changes by repeated-measures MANOVA. 
Adjustment for age; gender and smoking did not affect the results
Endothelial functional index was calculated as FMD/GTN as an index of endothelium dependent vasodila-
tation. Reflection index indicates the difference in pulse wave reflection before and after a subcutaneous 
injection of the beta-2 adrenoceptor agonist terbutaline
FMD flow mediated vasodilatation, GTN glycerine trinitrate
Week Doxazosin Ramipril P by repeated-meas-
ures ANOVA
FMD (%) 0 6.3 ± 4.4 5.3 ± 4.2 Time 0.34
12 5.5 ± 3.1 4.5 ± 4.3 Group 0.75
∆ 0 to 12 −0.3 ± 1.0 −1.1 ± 1.0 Time × Group 0.57
GTN (%) 0 15.5 ± 6.8 14.4 ± 7.0 Time 0.92
12 14.4 ± 7.0 14.4 ± 6.9 Group 0.97
∆ 0 to 12 −0.5 ± 1.3 0.3 ± 1.3 Time × Group 0.67
Endothelial functional index 0 0.47 ± 0.38 0.49 ± 0.56 Time 0.98
12 0.51 ± 0.41 0.44 ± 0.64 Group 0.90
∆ 0 to 12 0.07 ± 0.12 0.07 ± 0.12 Time × Group 0.42
Reflection index (%) 0 −7.3 ± 2.8 −6.8 ± 3.2 Time 0.68
12 −6.6 ± 3.1 −7.7 ± 3.8 Group 0.54
∆ 0 to 12 0.3 ± 0.9 −0.8 ± 1.0 Time × Group 0.43
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improvement of endothelial dysfunction by antihyperten-
sive treatment [45, 52].
There are several strengths to this double-blind rand-
omized controlled study conducted in mostly never treated 
hypertensive patients. First, we compared the effects of 
blocking the RAAS with alpha 1-adrenoceptor blockade 
as an active control to assess the potential confounding 
effects of BP reduction by the ACE inhibitor. In addition, 
potential residual confounding effects of the magnitude of 
BP reduction were accounted for in the statistical analyses. 
However, the greater reduction in BP by ramipril than by 
doxazosin could have influenced our results on indices of 
vascular function. Second, we simultaneously studied sev-
eral vascular beds. Third, we used several methods to eval-
uate endothelial function, and we included tests for both 
endothelium dependent and independent vasodilatation. 
However, there are important limitations to consider. First, 
the study population was of limited size, although this was 
justified by proper calculations of the required sample size. 
This may explain why we did not find changes in endothe-
lial function by treatment. Second, the treatment period 
was 12 weeks and we cannot exclude that prolonged treat-
ment could reveal other results. However, effects on BP and 
indices of aortic stiffness were already evident, and others 
have shown that changes in endothelial function can be 
demonstrated within 8–12 weeks in different study groups 
[46, 53]. Finally, although female sex hormones can influ-
ence endothelial function, we did not control for follicular/
luteal phase of the menstrual cycle. However, very few 
patients were premenopausal and the potential confounding 
effects of menstrual cycle phase on our results are consid-
ered small.
In conclusion, doxazosin and ramipril similarly reduced 
central BP more than brachial BP, suggesting that both 
neurogenic sympathetic vasoconstriction and the RAAS 
are important for the control of central and peripheral BP. 
Table 5  Treatment effects on skin microcirculation, as assessed by laser Doppler fluxmetry
Median values and interquartiles or mean values ± SEM (for differences) from 27 to 33 subjects in each treatment group, including all subjects 
with valid measurements at week 0 or 12. Skin microvascular flux is expressed in arbitrary units. P denotes significant changes by repeated-
measures ANOVA
∆ denotes the difference between rest and maximum values. Maximal hyperaemia was measured by local heating to 44 °C
Ach acetylcholine, SNP sodium nitroprusside
Week Doxazosin Ramipril P by repeated-measures 
ANOVA
Ach peak flux 0 35.5 [21.0–61.7] 32.8 [17.8–62.4] Time 0.96
12 40.8 [20.1–66.5] 27.7 [19.0–52.6] Group 0.35
Ach peak flux change week 0 to 12 0.6 ± 8.9 −2.2 ± 5.0 Time × group 0.82
Ach ∆ peak flux 0 29.0 [16.9–49.0] 25.1 [11.0–45.1] Time 0.04
12 35.0 [15.7–57.0] 23.1 [14.3–45.1] Group 0.24
Ach ∆ peak flux change week 0 to 12 0.6 ± 8.1 −0.9 ± 4.4 Time × group 0.87
SNP peak flux 0 57.5 [33.4–77.9] 46.2 [33.9–83.8] Time 0.38
12 60.0 [44.0–81.7] 42.5 [26.4–87.4] Group 0.23
SNP peak flux change week 0 to 12 −0.3 ± 10.3 −9.1 ± 8.4 Time × group 0.49
SNP ∆ peak flux 0 52.2 [27.4–71.2] 38.6 [27.6–75.2] Time 0.27
12 53.1 [34.7–72.9] 36.3 [17.7–83.1] Group 0.24
SNP ∆ peak flux change week 0 to 12 −0.5 ± 9.7 −7.8 ± 7.8 Time × group 0.56
Ach/SNP peak flux 0 0.57 [0.40–0.96] 0.53 [0.41–0.98] Time 0.28
12 0.79 [0.29–1.41] 0.79 [0.38–1.28] Group 0.46
Ach/SNP peak flux change week 0 to 12 0.26 ± 0.34 0.15 ± 0.20 Time × group 0.77
Ach/SNP ∆ peak flux 0 0.48 [0.38–0.99] 0.42 [0.30–0.91] Time 0.16
12 0.77 [0.23–1.51] 0.60 [0.29–1.49] Group 0.24
Ach/SNP ∆ peak flux change week 0 to 12 0.57 ± 0.53 0.23 ± 0.23 Time × group 0.54
Max hyperaemia 0 61.9 [38.4–78.1] 58.0 [40.0–71.7] Time 0.28
12 54.5 [40.4–73.6] 56.8 [34.6–68.3] Group 0.73
Max hyperaemia change week 0 to 12 −8.3 ± 7.9 −2.6 ± 4.5 Time × group 0.84
Max ∆ hyperaemia 0 53.5 [33.8–72.6] 47.6 [34.7–65.8] Time 0.19
12 49.0 [32.8–62.9] 52.9 [25.2–62.3] Group 0.67
Max ∆ hyperaemia change week 0 to 12 −8.9 ± 7.4 −1.2 ± 4.2 Time × group 0.98
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Ramipril reduced indices of aortic stiffness, suggesting that 
the effects of ACE inhibitor therapy go beyond the effects 
of BP reduction. However, we were unable to demonstrate 
an effect of treatment on endothelial function. Evidence 
of endothelial dysfunction and possible improvement by 
antihypertensive treatment might require more advanced 
hypertensive disease.
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